UroGen Pharma Ltd 8-K, filed Sep 12, 2022
UroGen Pharma Ltd. (URGN)
8-K
2022-09-12
For: 2022-09-08
View Original
Added on
April 07, 2026
About this 8-K
UroGen Pharma Ltd filed this 8-K on September 12, 2022, reporting on events of September 8, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2022
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: +1 (646 ) 768-9780
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange
on which registered |
|
par value NIS0.01 per share |
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(d)
On September 8, 2022, Leana Wen, M.D., MSc was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders and was also appointed to the Audit Committee of the Board.
In accordance with the Company’s 2019 Officers’ Compensation Policy, Dr. Wen received an initial option grant to purchase 20,000 ordinary shares of the Company (“Ordinary Shares”). The option vests in equal quarterly installments for 12 quarters. Dr. Wen is also eligible to receive an annual retainer of $40,000 for her service on the Board, an additional annual retainer of $7,500 for her service on the Audit Committee of the Board, and an annual option grant to purchase 10,000 Ordinary Shares on the date of each annual shareholder meeting of the Company.
The Company also entered into its standard form of indemnity agreement for directors and officers with Dr. Wen, a copy of which is filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UROGEN PHARMA LTD.
|
|||
|
Date: September 12, 2022
|
By:
|
/s/ Don Kim
|
|
|
Don Kim
|
|||
|
Chief Financial Officer
|
|||